December 19, 2018
2 min read

New flu guidelines emphasize testing, treatment of high-risk patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

New clinical practice guidelines from the Infectious Diseases Society of America emphasize the need to test and promptly treat patients at high risk for seasonal influenza-related complications, including pregnant women, young children, patients who are extremely obese and those who have a weakened immune system.

The guidelines, which update those issued in 2009 before the H1N1 influenza pandemic, were published today in Clinical Infectious Diseases.

“Influenza can be serious, especially for the sizable group of people at high risk,” Timothy M. Uyeki, MD, MPH, MPP, co-chair of the guidelines committee and chief medical officer in the CDC’s Influenza Division, said in a statement. “Annual influenza vaccination is the best way to prevent influenza, but it is not 100% effective. Those at high risk need to be encouraged to seek medical care right away if they develop influenza symptoms during influenza season.”

The IDSA noted some of the key recommendations:

  • Patients at high risk for influenza-related complications should be tested and begin antiviral treatment promptly if they are sick enough to be hospitalized with influenza symptoms.
  • Any outpatients with a diagnosis of influenza who are at high risk for complications should receive antiviral treatment as soon as possible.
  • Newer and highly accurate molecular tests — such as nucleic acid amplification tests — should be used instead of rapid-influenza diagnostic tests, which often produce false-negative results.
  • Antivirals should be prescribed to patients at high risk for influenza-related complications even if they have been sick for more than 2 days.
  • Patients at high risk for influenza-related complications who are being admitted to the hospital with suspected influenza should be started immediately on antiviral treatment without waiting for the results of molecular testing.
  • Providers caring for patients at high risk for complications who have become seriously ill with influenza should consult with an infectious disease physician.

patient speaking with a doctor
The IDSA issued new clinical practice guidelines on diagnosing and treating influenza for the first time since 2009.
Source: Adobe Stock

“High-risk individuals who are hospitalized with flu complications are at an increased risk for serious bacterial infections and infectious diseases physicians’ expertise is critical to ensuring they receive the best care,” Andrew T. Pavia, MD, co-chair of the guidelines committee and chief of the division of pediatric infectious diseases at the University of Utah, said in a statement. “ID doctors also can provide guidance when a patient who has the flu is not responding to antiviral treatment or is getting worse.”

The guidelines were finalized before the FDA approved baloxavir marboxil (Xofluza, Genentech) in October and do not include recommendations on its use, the authors noted.

Baloxavir marboxil is the first new antiviral influenza treatment with a novel mechanism of action approved by the FDA in almost 20 years. Phase 3 data showed that it reduces the duration of influenza symptoms by more than 1 day and is similarly effective compared with oseltamivir. It also has demonstrated efficacy against a wide range of influenza viruses, including those resistant to oseltamivir and avian influenza strains H7N9 and H5N1, in nonclinical studies.

The current influenza season has been mild in comparison to the 2017-2018 season, in which an estimated 900,000 people were hospitalized and 80,000 died from influenza.


Uyeki TM, et al. Clin Infect Dis. 2018;doi:10.1093/cid/ciy866.

Disclosures: Pavia reports receiving grants from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH, NIAID/Biofire, and the CDC, other support from Antimicrobial Therapy Inc., and personal fees from WebMD and Johnson & Johnson, outside the submitted work. Ueki reports no relevant financial disclosures. Please see the guidelines for a list of all other authors’ relevant financial disclosures.